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S330 Poster Session IItransplanted with sex-mismatch CD34+ and CD3+ cells. Only when
mice were transplanted with a very low CD3:CD34 cell ratio (0.1:1)
a mix chimerism of huCD45+ CD3+ (21611%) T cells, CD19+
(4469%) B cell, CD34+ cells (361%), CD33+ myeloid cells
(1461%) and CD14+ monocytes (661%) was observed. To investi-
gate whether a single T cell population could cause stem cell rejec-
tion, mice were transplanted with selected CD3+CD4+ or
CD3+CD8+ T cells and CD34+ cells at 1:1 ratio. Rejection was ob-
served in 100% of mice transplanted with human CD3+CD4+ cells.
CD4+ cells in marrow and spleen were mostly CD45RA+. Instead,
mice transplanted with human CD3+CD8+ cells showed a mixed
chimerism of T, B and myeloid cells both in marrow and spleen.
Spleen was larger in recipients of CD4+ than CD8+ cells (p 5
0.005). Finally, spleen cells obtained from mice transplanted with
CD4+ or CD8+ cells were tested in-vitro as responders against irra-
diated CD34+ cells in mixed leucocyte cultures. Controls included
CD4+ or CD8+ cells that were frozen at the time of transplant.
Spleen CD4+ cells and both CD4+ and CD8+ control cells prolifer-
ated after stimulation with CD34+ cells, whereas spleen CD8+ cells
were unresponsive in-vitro. These results show that alloreactive
CD4+ T cells serve an important role in stem cell rejection while
CD8+ T cells appear to facilitate immune tolerance. Our work
also supports the use of NSG mice to analyze the mechanisms of
stem cell rejection or graft failure.339
HEMATOPOIETIC CELL TRANSPLANTATION CO-MORBIDITY INDEX
(HCT-CI) TO PREDICT NON RELAPSE MORTALITY (NRM) AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Colella, M.P., Miranda, E.C.M., Aranha, F.J.P., Fernandes-
Junior, V.C.A., Medina, S.M., de Souza, C.A., Vigorito, A.C. University
of Campinas, Campinas, Sao Paulo, Brazil
In recent decades, several advances were made in the management
of patients (pts) who underwent allogeneic hematopoietic stem cell
transplantation (HSCT). Tools that could predict TRM, based on
pre HSCT characteristics and co-morbidities were always sought.
Some of these tools are the modified hematopoietic cell transplanta-
tion co-morbidity index (HCT-CI).Our aim was to apply the
modified HCT-CI and correlated it with overall survival (OS) and
non-relapsemortality (NRM).This analysis include patients who un-
derwent an allogeneic HSCT, for malignant and non malignant he-
matological diseases, after high or low dose conditioning regimens,
from related and unrelated donor, from 1993 to 2010. Each co-mor-
bidity was assigned an integer weight, and theHCT-CI score was the
sum of this integer weights. The patients were then assigned to one
of the risk groups 0, 1, 2 and 3 ormore. Kaplan-Meier was applied for
estimation of overall survival. NRMwas estimated by cumulative in-
cidence considering primary relapse disease as competing risk.457
pts were analyzed at the beginning. However, 331 (72.4%) were
evaluable, 126 (27.6%) were excluded when at least one parameter
was missing. 208 (63%) were male with a median age of 36.5 (5-
65) years, 249 (75%) pts received high dose (HD) conditioning
and 82 (25%) low dose (LD). HCT-CI in HD was: 127 (51%) score
0; 39 (16%) score 1; 19 (7%) 2 and 64 (26%) score $ 3; in LD 33
(40%) score 0; 14 (17%) score 1; 8 (10%) score 2 and 27 (33%) score
$ 3. The median follow up in HD was 22 months (0-201) and 9 (0-
203) in LD.The adjustedOS at 10 year forHD conditioning accord-
ing to the HCT-CI was 55% for score 0, 34% for score 1-2 & 34%
for score$ 3 and for LD conditioning was 58% for score 0, 53% for
score 1-2 & 15% for score $ 3 (p\ 0.0001). The NRM rate in the
HD cohort was 32% in the pts with a score 0, 42% for score 1-2
and 53% in the score $ 3. In the LD cohort, the NRM was 23%
in the pts with a score of 0; 35% for score 1-2 and 54% in the score
$ 3 (p 5 0.002). The adjusted OS for conditioning type in patients
with cardiac valve disease was associated to a lower OS (29% and
33% p 5 0.002) whereas mild hepatic involvement was just signifi-
cant in the HD cohort. The OS and NRM were worse for score $
3 either in HD and LD groups. The heart valve disease emerged
as a worse outcome in both conditioning type and mild hepatic in-
volvement only in HD group. The HCT-CI showed to be a valid
tool to predict outcome after allogeneic HSCT.340
OUTCOMES OF MANTLE CELL LYMPHOMA AFTER ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Costa, R.1, Palmer, J.2, Shen, Y.2, Paris, T.2, Popplewell, L.1,
Kogut, N.M.3, Forman, S.J.1, Nademanee, A.1 1City of Hope National
Medical Center, Duarte, CA; 2City of Hope National Medical Center,
Duarte, CA; 3Southern California Kaiser Permanente- City of Hope
Transplant Program, Los Angeles, CA
Background: Mantle cell lymphoma (MCL) commonly has an ag-
gressive course and short survival with conventional chemotherapy.
Allogeneic stem cell transplantation (allo-HSCT) is a potentially cu-
rative treatment for a subset of MCL patients.
Methods: We conducted a retrospective analysis including 41 con-
secutive MCL patients who underwent allo-HSCT. Patients with
the blastic variant of MCL; extensive marrow involvement; multiple
relapses after conventional chemotherapy; relapse after autologous
stem cell transplantation (ASCT); unable to collect stem cells to un-
dergo ASCT were considered eligible for allo-HSCT.
Patients:Median age was 54 years (range: 32-70). Median time from
diagnosis to transplant was 18 months (range: 5.4-118). Disease sta-
tus at allo-HSCT included CR1 (n 5 7), induction failure (n 5 13),
1st relapse (n5 13);.1st relapse (n5 8). 31 patients (76%) had stage
IV disease at diagnosis. Median number of prior regimens was 3
(range: 1-7). 35 patients (85%) had chemosensitive disease. 25
patients received allo-HSCT from a matched sibling and 16 from
unrelated donors. Conditioning regimens were fludarabine/melpha-
lan-based (n5 29), or TBI-based (n5 12). Most (80%) received pe-
ripheral blood stem cells. 23 (56%) received tacrolimus and
sirolimus; 18 received cyclosporine or tacrolimus with methotrexate
(n 5 12) or cellcept (n 5 6) for GVHD prophylaxis.
Results: At a median follow-up of 1.7 years, 59% of the patients
were still alive. The estimated 5-year overall and progression free-
survival was 51% (95% CI, 31% - 68%) and 30% (95% CI, 14% -
48%), respectively.The 5-year cumulative incidence of relapse and/
or progression was 43% (95% CI, 26% - 63%). The incidence of
acute and chronic GVHD was 56% and 63%, respectively. The
1-year and 5-year non-relapse related mortality (NRM) was 15 %
(95% CI, 7% - 29%) and 27% (95% CI, 15% - 43%). Factors asso-
ciatedwith increased risk of death and/or disease relapse/progression
were: time from diagnosis to transplant, advanced disease status at
transplant and prior ASCT.Patients transplanted after one or more
relapse events were at 7.28 times the risk of failure compared to those
in first CR1 (95%CI: 0.94 - 56.5; p 5 0.06).
Conclusions:These results suggest that long-term disease control is
possible after allo-HSCT for a subset of patients with MCLwith ac-
ceptable toxicity. Allo-SCT during CR1may offer long-term disease
control in patients with blastoid variant or those unable to undergo
autologous SCT.341
ASSESSMENT OF LIVER FIBROSIS BY DIAGNOSTIC VALUE OF TRANSIENT
ELASTOGRAPHY (FibroScan) IN THE IN PATIENTS WITH b-THALASSE-
MIA MAJOR CONSIDERED AS CANDIDATES FOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Hamidieh, A.A.1, Poustchi, H.2, Shazad, B.1, Jalili, M.1, Hamdi, A.1,
Behfar, M.1, Jalali, A.1, Malekzadeh, R.2, Ghavamzadeh, A.1 1Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction: Transient elastography (TE) is a valuable non-inva-
sive method to assess liver fibrosis. The present study aimed to eval-
uate the diagnostic value of TE in the assessment of hepatic fibrosis
in patients with b-thalassemia major (TM) who are candidates for
hematopoietic stem cell transplantation.
Method:We prospectively assessed the results of TE in 41 b-thalas-
semia major patients (median age of 7 years; range 2.6-20 years;
65.9%male) who were candidates for hematopoietic stem cell trans-
plantation (HSCT) and compared these results with the histological
fibrosis stage from liver biopsies. The diagnostic values were com-
pared by calculating the area under the receiver operating character-
istic curves (AUROCs).
Poster Session II S331Results: Liver stiffness was significantly correlated with thalassemia
classification (p 5 0.001), iron deposition (p 5 0.003) and fibrosis
stage (p\0.001).MedianTE values were significantly different in pa-
tients with severe fibrosis (stage 3-5) 4.5 (60.8 SD) kPa from those
with mild or no fibrosis (stage 0-2) 3.9 (62.8 SD) kPa (p 5 0.000).
The AUROC for prediction of high fibrosis stages (3-5) was 0.802
(95% confidence interval [CI]: 0.665-0.938) with cut-off of 4.35
kPa with 81.8% sensitivity (95% CI: 52.3-94.9) and 70.0% specific-
ity (95% CI: 52.1-83.3).
Conclusion: Our results demonstrate that transient elastography is
a reliable non-invasive tool to evaluate liver iron content and fibrosis
in patients with b-thalassemia major who are candidates for hemato-
poietic stem cell transplantation and can be an alternative to liver bi-
opsy. Moreover, it is a valuable tool to follow-up the liver status in
patients with b-thalassemia major after transplantation.342
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR SECOND-
ARY ACUTE MYELOID LEUKEMIA EVOLVING FROM MYELODYSPLASTIC
SYNDROME
Park, Y.-H., Lee, J.-H., Lee, K.-H., Kim, D.-Y., Kim, S.-D., Choi, Y.,
Seol,M., Lee, Y.-S., Kang, Y.-A., Jeon,M., Lee, J.-H. AsanMedical Cen-
ter, Seoul, Korea
Background: Secondary acute myeloid leukemia (AML) evolving
from myelodysplastic syndrome (MDS) is associated with a poor
prognosis and long-term survival is expected in only a small propor-
tion without allogeneic hematopoietic cell transplantation (HCT).
Methods:Weevaluated clinical outcomes of 37 consecutive patients
who underwent allogeneic HCT for secondary AML evolving from
MDS between January 1997 and April 2010 in a single institute. We
also tried to identify prognostic factors for the outcomes.
Results:Median age of the patients, 22 males and 15 females, was 46
years (range, 25-70). Median duration from diagnosis of MDS to
AML evolution was 2.8 months (range, 0.2-31.0). Before evolution
to AML, MDS was treated with hypomethylating agents in 11 pa-
tients, intensive chemotherapy in 1, and supportive care only in 25.
Twenty-six patients received induction chemotherapy for AML evo-
lution and 14 of them (54%) attained complete remission (CR). All
patients were well engrafted at a median day 15 (range, 6-39).
Nine of 37 patients (24.3%) developed acute GVHD and 13 of 26
assessable patients (50.0%) developed chronic GVHD. After a me-
dian follow-up duration of 38.0 months (range, 4-164), 18 patients
died of disease progression or recurrence (n 5 10) or non-relapse
causes (n 5 8). The 3-year probabilities of overall survival (OS), re-
lapse-free survival (RFS), and non-relapse mortality (NRM) were
47%, 65%, and 24%, respectively. Multivariate analyses revealed
that female sex (vs. male; HR, 4.6; p5 0.006), reduced-intensity con-
ditioning regimen (vs. myeloablative; HR, 4.0; p5 0.030), and hypo-
methylating therapy or intensive chemotherapy for MDS (vs.
supportive care only; HR, 3.7; p5 0.012) were independently unfa-
vorable prognostic factors for OS; shorter duration (\ 4 months)
from AML evolution to HCT (vs. $ 4 months; HR, 0.245; p 5
0.047) and reduced-intensity conditioning regimen (vs. myeloabla-
tive; HR, 6.1; p 5 0.040) were unfavorable prognostic factors for
RFS; there was no independent prognostic factor for NRM. Patients
who developed acute GVHD showed a trend for superior RFS (p 5
0.058), but inferior NRM (p 5 0.127). Patients who developed
chronic GVHD had higher OS (p 5 0.006) and RFS (p 5 0.031).
Conclusions: Allogeneic HCT was an effective therapy for second-
ary AML evolving fromMDS. Clinical outcomes were inferior with
reduced-intensity conditioning than myeloablative conditioning.
Presence of graft-versus-leukemia effects was evident.343
PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANTATION
FROM HAPLOIDENTICAL DONORS FOLLOWING REDUCED INTENSITY
CONDITIONING (RIC) FOR HIGH-RISK HEMATOLOGIC MALIGNANCIES
Raj, K.1, Streetly, M.1, Kazmi, M.1, Harringon, E.2, Getzendaner, L.C.2,
Lee, S.J.2,3, O’Donnell, P.V.2,3 1Guy’s and St. Thomas Hospital, King’sHealth Partners, London, United Kingdom; 2Fred Hutchinson Cancer Re-
search Center/Seattle Cancer Care Alliance, Seattle, WA; 3University of
Washington, Seattle, WA
Donor availability can be a significant obstacle to allogeneic
blood or marrow transplantation (BMT). Single- and multi-center
studies have shown that partially HLA-mismatched (haploidentical)
bone marrow from family members is a suitable source of donor
cells, thus extending this potentially curative treatment to patients
who lack HLA-matched donors. Use of PBPC instead of marrow
for haploidentical transplantation may allow wider applicability of
this approach but there is concern about risk of acute and chronic
GvHD due to the 5-10-fold higher number of T-cells in the
allograft.
We report preliminary results on 14 patients with HL or NHL
and 4 patients with MDS or leukemia (median age 51 yr) who re-
ceived allogeneic transplantation of T-replete PBPC from haploi-
dentical donors at our two centers. We used the protocol
reported by Brunstein, et al. (Blood 118:282 [2011]) except that
PBPC were substituted for bone marrow as the graft source. RIC
consisted of 30 mg/m2/d of fludarabine on days -6 to -2, 14.5
mg/kg/d of cyclophosphamide on days -6 and -5 and 200 cGy
TBI on day -1. PBPC were mobilized and collected in the standard
manner. GvHD prophylaxis included post-transplant cyclophos-
phamide (50 mg/kg/d on days +3 and +4) followed on day +5 by
standard dosing of tacrolimus and mycophenolate. The median
number of HLA-mismatches in the HvG and GvH directions
were 5 and 4, respectively. Allografts contained a median of 6 x
106 CD34 cells/kg and 18 x 107 CD3 cells/kg. Median times to
neutrophil and platelet recovery were 16 and 17 d, respectively.
One patient (6%) rejected their graft and recovered autologous he-
matopoiesis. All other recipients were 100% donor chimeras by day
+28. Grade II acute GvHD was observed in 11 of 16 (69%) evalu-
able patients and Grade III GvHD was observed in one patient
(6%). No chronic GvHD by NIH criteria was observed in patients
who survived beyond day +100. Three of 18 (16%) patients died of
non-relapse causes, all due to infection. Median follow-up of sur-
viving patients is short. Six patients have relapsed (4 of 14 lympho-
mas including 3 patients with ATLL and 1 of 4 patients with
myeloid malignancies). Our results suggest that PBPC can be
substituted for marrow as the donor source in haploidentical trans-
plantation with low rates of rejection, acute and chronic GvHD and
NRM that are similar to those observed after transplantation of
haploidentical bone marrow using this protocol.344
CHIMERISM TESTINGWITH REDUCED INTENSITY INTRAVENOUS BUSUL-
FAN-BASED CONDITIONING REGIMENS: ONCE IS ENOUGH
Bredeson, C.1, Burkart, J.2, Zhu, X.2, Sun, Y.3, LeRademacher, J.2,
Pasquini,M.2, Armstrong, E.3, Rizzo, J.D.2, Kato, K.3 1The OttawaHos-
pital, Ottawa, ON, Canada; 2CIBMTR, Medical College of Wisconsin,
Milwaukee, WI; 3Otsuka Pharmaceutical Development and Commercial-
ization Inc., Princeton, NJ
The CIBMTR is conducting a non-inferiority study of IV busul-
fan-based conditioning regimens vs. traditional ablative cyclophos-
phamide and TBI in patients (pts) with myeloid malignancies
undergoing related or unrelated SCT. Of 1750 pts, we describe
the practices and outcomes of chimerism testing in 155 pts who re-
ceived RIC in this study. 7 had no chimerism testing; data is avail-
able on 140 pts. A total of 807 chimerism assays were performed.
Initial chimerism testing was most commonly performed at day
30 (95/140pts) while only a small percentage had their first chime-
rism ./ 5 90 days post-SCT (19/140pts). Chimerism testing was
performed at a median of 3 (1-6) time points with a median of 5
(1-24) separate assays per patient. Multiple cell types (at least 3
types) were assayed (e.g. BM +/- PB MNC +/- lymphocytes +/- lin-
eage specific cells) in 45 pts, often at one time point. Other com-
mon patterns of testing in a single episode of care were BM +
PBMC (n32), PBMC only (n23), PB T and B cells (n18), BM
only (n13) and other combinations (n9). In 62 instances chimerism
was performed on the BM and PB at the same time. BM chimerism
differed by \10% from PBMC in 21, myeloid cells in 15 and T
